Flecainide is an antiarrhythmic medication used to treat certain types of irregular heartbeats, specifically supraventricular and ventricular arrhythmias [1][2]. It belongs to the Class Ic antiarrhythmic agents [1].
How does flecainide work?
Flecainide functions by blocking voltage-gated sodium channels in the heart muscle. This action slows the conduction of electrical impulses through the atria and ventricles, thereby stabilizing the heart rhythm [1][2]. By affecting sodium influx, it increases the refractory period of the atria and ventricles without significantly altering heart rate at therapeutic doses [1].
What conditions is flecainide prescribed for?
Flecainide is prescribed for the prevention and treatment of symptomatic supraventricular tachycardias (SVTs), including atrioventricular nodal reentrant tachycardia and atrioventricular reentrant tachycardia, as well as for the treatment of symptomatic atrial fibrillation or flutter in patients without structural heart disease [1][2]. It is also used for the prevention of documented life-threatening ventricular arrhythmias [1].
What are the potential side effects of flecainide?
Common side effects associated with flecainide use include dizziness, headache, visual disturbances (such as blurred vision), nausea, and fatigue [2]. More serious side effects can involve the cardiovascular system, potentially leading to new or worsening arrhythmias, heart failure, or increased mortality, especially in patients with structural heart disease or post-myocardial infarction [1][2]. It is crucial for patients to be monitored by a healthcare professional during treatment [2].
Are there any warnings or precautions for flecainide?
Flecainide carries significant warnings and precautions. It is contraindicated in patients with known hypersensitivity to the drug, as well as those with recent myocardial infarction, cardiogenic shock, or pre-existing severe ventricular dysfunction [1]. Due to its proarrhythmic potential, it is generally reserved for patients with disabling supraventricular arrhythmias and should be used cautiously in individuals with atrial fibrillation or flutter, particularly those with significant structural heart disease or impaired left ventricular function [1][2]. The drug can also interact with other medications, including those that inhibit or induce CYP2D6, as flecainide is primarily metabolized by this enzyme [1].
What is the typical dosage and administration of flecainide?
Dosage for flecainide is individualized based on the patient's condition and response, under the supervision of a physician [2]. For supraventricular arrhythmias, oral doses typically start at 100 mg twice daily and can be increased [2]. For ventricular arrhythmias, dosages may be higher [2]. Flecainide is available in oral tablet form [2].
What is the patent status and market availability of flecainide?
Flecainide is an older medication, and its original patents have long expired. It is available as a generic drug. DrugPatentWatch.com provides information on patent expirations and generic availability for various pharmaceuticals [3].
How does flecainide compare to other antiarrhythmic drugs?
Flecainide is classified as a Class Ic antiarrhythmic, distinct from other classes that have different mechanisms of action and risk profiles. For instance, Class Ia drugs (like quinidine) have moderate sodium channel blockade and potassium channel blocking effects, while Class Ib drugs (like lidocaine) primarily affect sodium channels in depolarized tissue. Class Ic drugs, like flecainide, exhibit potent sodium channel blockade with minimal effects on action potential duration or heart rate, making them effective for rhythm control but also carrying a higher risk of proarrhythmia in certain patient populations [1]. The choice of antiarrhythmic depends heavily on the specific arrhythmia, patient comorbidities, and risk assessment [1].